BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 20954988)

  • 1. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
    Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
    Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
    Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
    Kaufman McNamara E; Curtis AR; Fleischer AB
    J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
    Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
    Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
    Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
    Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
    Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
    Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
    Franz DN; Leonard J; Tudor C; Chuck G; Care M; Sethuraman G; Dinopoulos A; Thomas G; Crone KR
    Ann Neurol; 2006 Mar; 59(3):490-8. PubMed ID: 16453317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE; De Bernardis G; Weber P; Lösch U
    Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
    Haemel AK; O'Brian AL; Teng JM
    Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
    JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.